These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
488 related articles for article (PubMed ID: 26455499)
21. Abouchaleh N; Gabr A; Ali R; Al Asadi A; Mora RA; Kallini JR; Mouli S; Riaz A; Lewandowski RJ; Salem R J Nucl Med; 2018 Jul; 59(7):1042-1048. PubMed ID: 29217739 [TBL] [Abstract][Full Text] [Related]
22. Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib. Kermiche-Rahali S; Di Fiore A; Drieux F; Di Fiore F; François A; Scotté M World J Surg Oncol; 2013 Aug; 11(1):171. PubMed ID: 23914915 [TBL] [Abstract][Full Text] [Related]
23. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079 [TBL] [Abstract][Full Text] [Related]
24. Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors. Edeline J; Crouzet L; Le Sourd S; Larible C; Brunot A; Le Roy F; Cattenoz C; Latournerie M; Gédouin D; Guillygomarc'h A; Boucher E Cancer Chemother Pharmacol; 2015 Jan; 75(1):215-9. PubMed ID: 25477009 [TBL] [Abstract][Full Text] [Related]
25. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. Casadei Gardini A; Faloppi L; De Matteis S; Foschi FG; Silvestris N; Tovoli F; Palmieri V; Marisi G; Brunetti O; Vespasiani-Gentilucci U; Perrone G; Valgiusti M; Granato AM; Ercolani G; Negrini G; Tamburini E; Aprile G; Passardi A; Santini D; Cascinu S; Frassineti GL; Scartozzi M Eur J Cancer; 2017 Nov; 86():106-114. PubMed ID: 28985579 [TBL] [Abstract][Full Text] [Related]
26. Apparent diffusion coefficient quantification as an early imaging biomarker of response and predictor of survival following yttrium-90 radioembolization for unresectable infiltrative hepatocellular carcinoma with portal vein thrombosis. Kokabi N; Camacho JC; Xing M; Qiu D; Kitajima H; Mittal PK; Kim HS Abdom Imaging; 2014 Oct; 39(5):969-78. PubMed ID: 24740759 [TBL] [Abstract][Full Text] [Related]
27. A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function. Yang H; Woo HY; Lee SK; Han JW; Jang B; Nam HC; Lee HL; Lee SW; Song DS; Song MJ; Oh JS; Chun HJ; Jang JW; Lozada A; Bae SH; Choi JY; Yoon SK Clin Mol Hepatol; 2017 Jun; 23(2):128-137. PubMed ID: 28494528 [TBL] [Abstract][Full Text] [Related]
28. Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis. Nakazawa T; Hidaka H; Shibuya A; Okuwaki Y; Tanaka Y; Takada J; Minamino T; Watanabe M; Kokubu S; Koizumi W BMC Gastroenterol; 2014 May; 14():84. PubMed ID: 24886354 [TBL] [Abstract][Full Text] [Related]
29. Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. Kim GA; Shim JH; Yoon SM; Jung J; Kim JH; Ryu MH; Ryoo BY; Kang YK; Lee D; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS J Vasc Interv Radiol; 2015 Mar; 26(3):320-9.e6. PubMed ID: 25612807 [TBL] [Abstract][Full Text] [Related]
30. Is radioembolization ((90)Y) better than doxorubicin drug eluting beads (DEBDOX) for hepatocellular carcinoma with portal vein thrombosis? A retrospective analysis. Akinwande O; Kim D; Edwards J; Brown R; Philips P; Scoggins C; Martin RC Surg Oncol; 2015 Sep; 24(3):270-5. PubMed ID: 26133576 [TBL] [Abstract][Full Text] [Related]
31. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial. Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK; BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083 [TBL] [Abstract][Full Text] [Related]
32. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis. Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644 [TBL] [Abstract][Full Text] [Related]
33. NEMESIS: Noninferiority, Individual-Patient Metaanalysis of Selective Internal Radiation Therapy with Venerito M; Pech M; Canbay A; Donghia R; Guerra V; Chatellier G; Pereira H; Gandhi M; Malfertheiner P; Chow PKH; Vilgrain V; Ricke J; Leandro G J Nucl Med; 2020 Dec; 61(12):1736-1742. PubMed ID: 32358087 [TBL] [Abstract][Full Text] [Related]
34. Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis. He MK; Zou RH; Li QJ; Zhou ZG; Shen JX; Zhang YF; Yu ZS; Xu L; Shi M Cardiovasc Intervent Radiol; 2018 May; 41(5):734-743. PubMed ID: 29327075 [TBL] [Abstract][Full Text] [Related]
35. Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization. Xing M; Kokabi N; Camacho JC; Kim HS BMC Cancer; 2018 Jan; 18(1):75. PubMed ID: 29329568 [TBL] [Abstract][Full Text] [Related]
36. Skeletal muscle quality predicts overall survival in advanced liver hepatocellular carcinoma treated with SIRT and sorafenib: A subanalysis of the SORAMIC trial. Surov A; Wienke A; Borggrefe J; Hinnerichs M; Seidensticker R; Öcal O; Schütte K; Zech CJ; Loewe C; van Delden O; Vandecaveye V; Verslype C; Gebauer B; Sengel C; Bargellini I; Iezzi R; Malfertheiner P; Berg T; Klümpen HJ; Benckert J; Gasbarrini A; Amthauer H; Sangro B; Ricke J; Seidensticker M United European Gastroenterol J; 2024 Oct; 12(8):1016-1027. PubMed ID: 39007783 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data. Ye SL; Chen X; Yang J; Bie P; Zhang S; Liu F; Liu L; Zhou J; Dou K; Yip CS; Yang X Tumour Biol; 2017 Mar; 39(3):1010428317695030. PubMed ID: 28349781 [TBL] [Abstract][Full Text] [Related]
38. The Safety and Efficacy of Combination Therapy of Sorafenib and Radiotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Study. Wada Y; Takami Y; Matsushima H; Tateishi M; Ryu T; Yoshitomi M; Matsumura T; Saitsu H Intern Med; 2018 May; 57(10):1345-1353. PubMed ID: 29279513 [TBL] [Abstract][Full Text] [Related]
39. Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma. Chow PK; Poon DY; Khin MW; Singh H; Han HS; Goh AS; Choo SP; Lai HK; Lo RH; Tay KH; Lim TG; Gandhi M; Tan SB; Soo KC; PLoS One; 2014; 9(3):e90909. PubMed ID: 24614178 [TBL] [Abstract][Full Text] [Related]
40. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study. Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]